Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
Quarterly research spending declined, while administrative expenses rose and included a one-time net litigation settlement expense.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Metagenomi Therapeutics (Nasdaq: MGX) received FDA clearance to begin human testing of MGX-001, its wholly owned hemophilia A treatment. The company plans to start the Phase 1/2 INTEGR8 trial in the first half of 2027 and provide initial safety, tolerability and Factor VIII activity data in the second half. Factor VIII is the blood-clotting protein deficient in hemophilia A. Expansion beyond the United States requires additional clinical clearances.
Third-quarter 2026 collaboration revenue fell to $2.184 million from $8.659 million a year earlier. Net loss widened to $21.126 million, or $0.56 per share, from $20.393 million, or $0.55 per share. Cash, cash equivalents and marketable securities totaled $101.674 million at September 30, versus $160.799 million at December 31, 2025. The company anticipates funding operations into 2028.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA clearance enables the first-in-human INTEGR8 trial of wholly owned MGX-001 in hemophilia A.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Metagenomi plans trial initiation in the first half of 2027 and initial data in the second half.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Metagenomi anticipates its cash runway will support operations into 2028.
- Moderate pointNine-month research and development expenses fell to $59.344 million from $72.932 million in 2025.
- Minor pointPreclinical MGX-001 studies showed normal-range Factor VIII activity in non-human primates and no detectable off-target editing.
5 minor points
- Minor pointEarlier non-human primate study showed durable Factor VIII activity over approximately 19 months.
- Minor pointThird-quarter research and development expenses fell to $17.532 million from $25.283 million a year earlier.
- Minor pointNine-month administrative expenses fell to $19.417 million from $20.013 million in 2025.
- Minor pointThird-quarter operating loss narrowed to $22.226 million from $22.839 million a year earlier.
- Minor pointMetagenomi continues evaluating additional disease indications using the gene-insertion approach employed in MGX-001.
Negative
- Moderate pointNine-month collaboration revenue declined to $3.175 million from $21.299 million in 2025.
- Moderate pointNine-month net loss widened to $71.667 million, or $1.90 per share, from $65.340 million, or $1.76.
- Moderate pointCash, cash equivalents and marketable securities declined to $101.674 million at September 30 from $160.799 million at December 31, 2025.
- Moderate pointThird-quarter administrative expenses rose to $6.878 million from $6.215 million, including a $1.2 million one-time net litigation settlement expense. 4.4% of market cap
- Minor pointInternational INTEGR8 expansion remains subject to clinical clearances in additional jurisdictions.
6 minor points
- Minor pointThird-quarter collaboration revenue declined to $2.184 million from $8.659 million a year earlier.
- Minor pointThird-quarter net loss widened to $21.126 million, or $0.56 per share, from $20.393 million, or $0.55.
- Minor pointNine-month operating loss widened to $75.586 million from $71.646 million in 2025.
- Minor pointThird-quarter interest income declined to $1.047 million from $2.214 million a year earlier.
- Minor pointNine-month interest income declined to $3.842 million from $7.586 million in 2025.
- Minor pointStockholders’ equity declined to $93.188 million at September 30 from $158.596 million at December 31, 2025.
Key Figures
- Trial phase
- Phase 1/2
- INTEGR8 trial of MGX-001
- Planned trial initiation
- First half of 2027
- INTEGR8 trial
- Initial clinical data
- Second half of 2027
- Safety, tolerability, and FVIII functional activity
- Cash and marketable securities
- $101.7 million
- As of September 30, 2026
- Anticipated cash runway
- Into 2028
- Operations
- R&D expenses
- $17.5 million vs. $25.3 million
- Three months ended September 30, 2026 vs. 2025
- G&A expenses
- $6.9 million vs. $6.2 million
- Q3 2026 vs. Q3 2025; Q3 2026 included a $1.2 million one-time net litigation settlement expense
- Net loss
- ($21,126 thousand) vs. ($20,393 thousand)
- Three months ended September 30, 2026 vs. 2025
Historical Context
-
MGX-001 presentation was scheduled, with a 2027 global trial planned subject to regulatory clearance.
-
Reported $120.7 million in cash and targeted a Q4 2026 IND filing, subject to clearance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
investigational new drug regulatory
factor viii (fviii) medical
adeno-associated virus (aav) medical
lipid nanoparticle (lnp) technical
guide rna technical
off-target editing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A
MGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one-time treatment for adults and children
Company plans to initiate the INTEGR8 clinical trial in the first half of 2027 and provide initial clinical data in the second half of 2027
EMERYVILLE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create potentially curative genetic medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for MGX-001, its lead, wholly owned program for the treatment of hemophilia A. The Company also reported financial results for the third quarter ended September 30, 2026, and provided business updates.
“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A,” said Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of Metagenomi Therapeutics. “MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production. This represents an exciting departure from prior approved gene therapy for hemophilia A that relied on episomal FVIII expression. The MGX-001 preclinical data demonstrated FVIII activity in the normal physiologic range and durable expression in non-human primates and no detectable off-target editing. In a landscape with no cure for hemophilia A, we believe MGX-001 has the potential to provide long-term benefit to both adult and pediatric patients. We plan to initiate the INTEGR8 global clinical trial in the first half of 2027 and provide initial clinical data, including safety, tolerability, and FVIII functional activity data, in the second half of 2027.”
Third Quarter 2026 and Recent Updates
MGX-001 – Hemophilia A Program
- IND clearance enables initiation of the INTEGR8 trial in the U.S. The Company also intends to expand the INTEGR8 trial to hemophilia treatment centers beyond the U.S., subject to clinical clearances in additional jurisdictions.
- The INTEGR8 Phase 1/2 trial of MGX-001 is designed to evaluate the safety and tolerability of MGX-001, and to identify a dose that achieves target FVIII activity levels in the normal physiologic range. The clinical trial is expected to be a global, multi-center, open-label, single-arm, dose escalation followed by dose expansion trial in adult patients with moderately severe to severe hemophilia A.
- Additional MGX-001 preclinical data, including the most recent efficacy and safety results, will be presented in an oral presentation (Abstract 952) at the 68th American Society of Hematology (ASH) Annual Meeting on Monday, December 14, 2026 in New Orleans.
Site-Specific Large Gene Integration for Other Protein Deficiency Diseases
- The Company continues to evaluate additional disease indications which may be treated by protein replacement via gene insertion leveraging the same site-specific large gene integration at the albumin locus as used in MGX-001. The potential for application in other diseases was previously demonstrated by the Company in non-human primates in another secreted protein disorder.
Third Quarter 2026 Financial Results
Cash Position: Cash, cash equivalents and available-for-sale marketable securities were
R&D Expenses: Research and development (R&D) expenses were
G&A Expenses: General and administrative (G&A) expenses were
About MGX-001
MGX-001 is an investigational, one-time genome editing treatment designed to provide life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to site-specifically integrate the FVIII gene in a “safe harbor” location within an intron of the albumin gene, leveraging the strong native albumin promoter to drive endogenous FVIII expression. MGX-001 consists of an adeno-associated virus (AAV) vector that delivers the promoterless FVIII gene cassette as donor DNA, and a lipid nanoparticle (LNP) that delivers mRNA encoding the Company’s proprietary Type V CRISPR nuclease, MG29-1, together with a guide RNA targeting the albumin gene. This represents a departure from prior approved gene therapy for hemophilia A that relied on episomal FVIII expression.
In preclinical studies in non-human primates (NHPs), MGX-001 demonstrated FVIII activity in the normal physiologic range, with clear dose dependency across both the AAV and LNP components, and, in an earlier study, durable FVIII activity over approximately 19 months. MGX-001 has also shown no detectable off-target editing in a series of orthogonal assays.
About Hemophilia A
Hemophilia A is the most common X-linked inherited and de novo bleeding disorder, largely affecting males, and is caused by a variety of mutations in the FVIII gene that all lead to loss of functional FVIII protein. Hemophilia A affects approximately 25,000 patients in the United States and an estimated 500,000 worldwide. Current standard-of-care treatments, including FVIII replacement therapy and bispecific antibody therapy, require lifelong, repeated dosing, are not curative and carry a risk of breakthrough bleeding.
About Metagenomi Therapeutics
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create potentially curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel CRISPR gene-editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site-specific deletion, insertion and correction.
MGX-001, the Company’s lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile with best-in-class treatment potential, including targeted genome editing and durable gene expression in a one-time treatment. The FDA has cleared the Company’s Investigational New Drug (IND) application for MGX-001, and the Company is advancing MGX-001 into the clinic in its global Phase 1/2 INTEGR8 trial. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children, potentially enabling a new standard of care for the treatment of hemophilia A. The Company is also currently pursuing indications leveraging the same site-specific large gene integration at the albumin locus as used in MGX-001 and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions include, but are not limited to, any statements relating to our product development programs, including the timing of and our ability to make regulatory filings such as INDs, the design and timing of the INTEGR8 trial and initial clinical data, expectations regarding MGX-001 including the preclinical profile with best-in-class treatment potential, statements regarding the Company’s plans to prioritize its preclinical pipeline and potential for value creation and sustainable growth, statements regarding upcoming milestones, statements concerning the potential of therapies and product candidates, statements concerning the impact of the organizational restructuring, statements concerning our anticipated cash runway, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; the risk that the FDA or other regulatory authorities may place a clinical hold on our clinical trials or that initiation of our clinical trials may be delayed; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and Form 10-Q and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
| Condensed Financial Statements Condensed Balance Sheet Data (Unaudited) | |||||||
| September 30, | December 31, | ||||||
| (In thousands) | 2026 | 2025 | |||||
| Cash, cash equivalents and available-for-sale marketable securities | $ | 101,674 | $ | 160,799 | |||
| Total assets | $ | 157,388 | $ | 221,103 | |||
| Total liabilities | $ | 64,200 | $ | 62,507 | |||
| Total stockholders’ equity | $ | 93,188 | $ | 158,596 | |||
| Total liabilities and stockholders’ equity | $ | 157,388 | $ | 221,103 | |||
| Condensed Statements of Operations (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| (In thousands, except share and per share data) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Collaboration revenue | $ | 2,184 | $ | 8,659 | $ | 3,175 | $ | 21,299 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 17,532 | 25,283 | 59,344 | 72,932 | ||||||||||||
| General and administrative | 6,878 | 6,215 | 19,417 | 20,013 | ||||||||||||
| Total operating expenses | 24,410 | 31,498 | 78,761 | 92,945 | ||||||||||||
| Loss from operations | (22,226 | ) | (22,839 | ) | (75,586 | ) | (71,646 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 1,047 | 2,214 | 3,842 | 7,586 | ||||||||||||
| Change in fair value of long-term investments | — | — | — | (1,292 | ) | |||||||||||
| Other income (expense), net | 53 | (2 | ) | 87 | (80 | ) | ||||||||||
| Total other income (expense), net | 1,100 | 2,212 | 3,929 | 6,214 | ||||||||||||
| Net loss before provision for income taxes | (21,126 | ) | (20,627 | ) | (71,657 | ) | (65,432 | ) | ||||||||
| Benefit from (provision for) income taxes | — | 234 | (10 | ) | 92 | |||||||||||
| Net loss | $ | (21,126 | ) | $ | (20,393 | ) | $ | (71,667 | ) | $ | (65,340 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.56 | ) | $ | (0.55 | ) | $ | (1.90 | ) | $ | (1.76 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 37,775,051 | 37,349,449 | 37,672,176 | 37,176,361 | ||||||||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Metagenomi start the MGX-001 INTEGR8 trial and report initial results?
Metagenomi plans to initiate INTEGR8 in the first half of 2027 and provide initial clinical data in the second half of 2027. The planned initial data include safety, tolerability and Factor VIII functional activity.
How long does Metagenomi expect its cash to fund operations?
Metagenomi anticipates its cash runway will support operations into 2028. Cash, cash equivalents and available-for-sale marketable securities totaled $101.674 million as of September 30, 2026.
Who will participate in Metagenomi's MGX-001 INTEGR8 trial, and how is it designed?
The Phase 1/2 INTEGR8 trial is expected to enroll adults with moderately severe to severe hemophilia A. It is designed as a global, multi-center, open-label, single-arm study, meaning treatment is known and there is no comparison group. Dose escalation followed by dose expansion will evaluate safety and tolerability and identify a dose achieving normal-range Factor VIII activity.
When will Metagenomi present additional MGX-001 preclinical results?
Additional MGX-001 preclinical efficacy and safety results will be presented orally on December 14, 2026, at the 68th American Society of Hematology Annual Meeting in New Orleans. The presentation is Abstract 952.